Apnimed (NASDAQ:APMD) Now Covered by Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Apnimed (NASDAQ:APMD) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating and a $60.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 134.10% from the company’s current price.

Separately, Wall Street Zen raised Apnimed to a “hold” rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $50.50.

Apnimed Stock Performance

Shares of NASDAQ APMD opened at $25.63 on Tuesday. Apnimed has a 12 month low of $16.12 and a 12 month high of $35.29.

Insider Activity

In related news, major shareholder Morningside Venture Investment bought 312,500 shares of Apnimed stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. This represents a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

About Apnimed

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.